Current therapeutic research, clinical and experimental · 2005
Ketolides in the treatment of community-acquired respiratory tract infections: A review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lipsky Martin S
Аннотация
BACKGROUND: The increasing prevalence of resistance to established antibiotics among key respiratory bacterial pathogens highlights a need for new antibacterial agents for the treatment of community-acquired respiratory tract infections (RTIs). Ketolides are a new class of antibiotics specifically developed for the treatment of RTIs.
OBJECTIVE: The aim of this review was to present the current status of treatment of RTIs with ketolides, focusing on telithromycin-the first ketolide to be approved by the US Food and Drug Administration for clinical use.
METHODS: TO GATHER EVIDENCE ON THE CURRENT STATUS OF KETOLIDES, A LITERATURE SEARCH WAS CONDUCTED USING MEDLINE (YEARS: 1990-2005; key terms: ketolides, telithromycin, and HMR3647).
RESULTS: Telithromycin shows strong in vitro activity against the major respiratorypathogens, including strains resistant to other antibiotics, as well as the atypical respiratory pathogens. The pharmacokinetic properties of telithromycin are compatible with once-daily dosing. Clinical trials have demonstrated that telithromycin 800 mg QD for 5 to 10 days is effective in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and mild to moderate community-acquired pneumonia. Overall, telithromycin is well tolerated by patients. Drug-drug interactions are similar to those reported for macrolides.
CONCLUSION: Evidence to date indicates that telithromycin is an effective andwell-tolerated empiric treatment for community-acquired RTIs.
OBJECTIVE: The aim of this review was to present the current status of treatment of RTIs with ketolides, focusing on telithromycin-the first ketolide to be approved by the US Food and Drug Administration for clinical use.
METHODS: TO GATHER EVIDENCE ON THE CURRENT STATUS OF KETOLIDES, A LITERATURE SEARCH WAS CONDUCTED USING MEDLINE (YEARS: 1990-2005; key terms: ketolides, telithromycin, and HMR3647).
RESULTS: Telithromycin shows strong in vitro activity against the major respiratorypathogens, including strains resistant to other antibiotics, as well as the atypical respiratory pathogens. The pharmacokinetic properties of telithromycin are compatible with once-daily dosing. Clinical trials have demonstrated that telithromycin 800 mg QD for 5 to 10 days is effective in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and mild to moderate community-acquired pneumonia. Overall, telithromycin is well tolerated by patients. Drug-drug interactions are similar to those reported for macrolides.
CONCLUSION: Evidence to date indicates that telithromycin is an effective andwell-tolerated empiric treatment for community-acquired RTIs.